Page 11 of 15 · 360 questions tagged semaglutide.
What I am working with: FLOW · mazdutide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including…
The case in front of me: SURMOUNT-OSA · oral semaglutide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers…
What I have: SELECT · dulaglutide. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…
Stated plainly: PIONEER-1 · cagrilintide. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I…
Stated plainly: SURMOUNT-3 · mazdutide. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I do…
What I am working with: SOUL · a GLP-1 receptor agonist. I would like help reading this properly rather than being told what conclusion to reach. I have the full…
The specifics, since they change the answer: ATTAIN-1 · semaglutide. Somebody stated this to me confidently and I would like to check it before repeating it. I would…
Setup, so nobody has to ask: TRIUMPH-1 · cagrilintide. I have read the primary source rather than the summary, which has left me with more questions. I understand the…
For reference: TRIUMPH-3 · ecnoglutide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…
The case in front of me: SURMOUNT-2 · oral semaglutide. I want to know whether there is evidence behind this or only repetition. I have checked the obvious registries…
The case in front of me: STEP 1 · oral semaglutide. I want to know whether there is evidence behind this or only repetition. I have checked the obvious registries and…
What I am working with: REDEFINE-1 · mazdutide. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary sources all…
The particulars: REDEFINE-1 · ecnoglutide. I would like to know whether this claim survives contact with evidence. If the answer is "nobody has tested that", I would…
Numbers first: FLOW · orforglipron. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…
Numbers first: mazdutide · semaglutide. I want to know what the trade-off actually is rather than which option is fashionable. I would rather have a defensible reason…
What I am working with: SURPASS-3 · cagrilintide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
What I have: mazdutide · retatrutide. I want to know what the trade-off actually is rather than which option is fashionable. I would rather have a defensible reason…
Setup, so nobody has to ask: PIONEER-1 · mazdutide. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary sources all…
For reference: tirzepatide · tirzepatide. I am trying to choose between two options that are usually discussed as though only one exists. I am not optimising for…
The specifics, since they change the answer: liraglutide · mazdutide. I am trying to choose between two options that are usually discussed as though only one exists.…
The specifics, since they change the answer: STEP 5 · survodutide. I would like to know whether this claim survives contact with evidence. If the answer is "nobody…
I have the full paper rather than the abstract, and the supplementary appendix. I understand the observation; what I do not understand is the mechanism behind it. I…
The particulars: SURPASS-3 · semaglutide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…
Numbers first: a GLP-1 receptor agonist · tirzepatide. I have used one of these for a while and I am considering switching, which requires a reason. What I care about…